Tuberc Respir Dis Search


Tuberc Respir Dis > Accepted Articles
DOI:    [Accepted]
Published online October 26, 2020.
Are patients with asthma and COPD preferred targets of COVID-19?
Belaid Bouazza, 1, Dihia Hadj-Said, 1, Karen A. Pescatore, 2, Rachid Chahed, 3
1Biochemistry and Microbiology Department, Mouloud Mammeri University of Tizi-Ouzou, Algeria
2Department of Psychology, Rowan University, Glassboro, New Jersey, United States
3Cabinet médical privé, spécialité de Pneumologie, Tizi-Ouzou, Algérie
Correspondence:  Belaid Bouazza, Tel: +213 561 980 787, 
Received: 6 September 2020   • Revised: 30 September 2020   • Accepted: 23 October 2020
The coronavirus pandemic, known as coronavirus disease 2019 (COVID-19), is an infectious respiratory disease caused by SARS-CoV-2, a novel coronavirus first identified in patients from Wuhan, China. Since December 2019, SARS-CoV-2 spread swiftly around world and infected more than 25 million people and caused more than 800,000 deaths in 188 countries. Chronic respiratory diseases such as asthma and COPD appear to be a risk factor for COVID-19; however, their prevalence remains controversial. In fact, studies in China reported lower rates of chronic respiratory conditions in patients with COVID-19 than in the general population, while the trend is reversed in the United States and Europe. Although the underlying molecular mechanisms of a possible interaction between COVID-19 and chronic respiratory diseases remain unknown, some observations can help to resolve them. Indeed, physiological changes, immune response, or medication used against SARS-CoV-2 may have greater impact on patients with chronic respiratory conditions, already debilitated by chronic inflammation, dyspnea, and the use of immunosuppressant drugs like corticosteroids. In this review, we discuss the importance and the impact of COVID-19 on asthmatics and COPD patients, the possible available treatments, and patient management during the pandemic.
Key Words: COVID-19, SARS-CoV-2, Chronic respiratory diseases, Asthma, and COPD
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 0 Crossref
  • 491 View
  • 84 Download
Related articles in Tuberc Respir Dis

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2020 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2community

Close layer
prev next